Search clinical trials for: Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed

Total 1317 results

Mount Vernon Cancer Centre at Mount Vernon Hospital

Unknown

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

Melanoma (Skin)

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC)

Extrapulmonary Small Cell Carcinoma

Italy
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Neuroendocrine Tumors | Neuroendocrine Carcinoma

China
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Uterine Cervical Neoplasms

Japan
NRG Oncology
National Cancer Institute (NCI)

Terminated

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...

United States, Canada
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States, China, Taiwan, Belgium, Australia, Japan, United Kingdom, Spain, France, Germany, Austria, Korea, Republic of, Hungary, Switzerland, Mexico, Norway, Italy, Turkey, Greece, Portugal, Netherlands, India, Romania, Canada, De... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Stage III Laryngeal Cancer AJCC v8 | Laryngeal Squamous Cell Carcinoma | Stage II Laryngeal Cancer AJCC v8

United States
Shanghai Pulmonary Hospital, Shanghai, China

Terminated

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

China
NCIC Clinical Trials Group

Completed

Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Head and Neck Cancer

Canada
University of Washington
National Cancer Institute (NCI)

Completed

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
First People's Hospital of Hangzhou

Unknown

A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer

Squamous Cell Lung Cancer

China
University College London Hospitals

Unknown

Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

Cervical Cancer

United Kingdom
University of Michigan Rogel Cancer Center

Recruiting

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer (ARTHOUSE)

Oropharynx Cancer | HPV-Related Carcinoma

United States
Xinjiang Medical University

Unknown

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Non-Small Cell Lung Cancer

China
Danish Oncological Lung Cancer Group

Terminated

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

Small Cell Lung Cancer | Extensive Disease | First-Line

Denmark
George Washington University

Active, not recruiting

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
Zhonglin Hao
University of Kentucky; BeiGene

Withdrawn

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER)

Esophageal Cancer | Esophagogastric Junction Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); North Central Cancer Treatment Group

Completed

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Mesothelioma

United States
Armando Santoro, MD

Terminated

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

NSCLC

Italy
Yonsei University

Withdrawn

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

NSCLC
University of Arizona
National Cancer Institute (NCI)

Completed

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Chang Gung Memorial Hospital
Taiwan Chest Disease Association

Completed

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Advanced Non-Squamous Non-Small Cell Lung Cancer

Taiwan
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Israel, Japan, Australia, Spain, Germany
AstraZeneca

Active, not recruiting

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)

Carcinoma, Non-Small-Cell Lung | Small Cell Lung Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States, Taiwan, Korea, Republic of, Japan, Spain
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaborators

Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (iCROSS)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Cervical Cancer

China
AbbVie

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Small Cell Lung Cancer

United States, Israel, Japan
Tata Memorial Centre
All India Institute of Medical Sciences, New Delhi; Amrita Institute of Medical...

Not yet recruiting

Surgery Vs Chemoradiation for Oropharyngeal Cancer- A Phase II/III Integrated Design Randomized Control Trial (SCOPE)

Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8

India
Yonsei University

Unknown

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Completely Resected NSCLC With Common EGFR Mutations

Korea, Republic of
NYU Langone Health

Completed

Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center

Terminated

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Mesothelioma

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

Gastric Cancer | Colorectal Cancer | Small Intestine Cancer | Ovarian Cancer | Peritoneal Cavity Cancer | Gastrointestinal Stromal Tumor | Gastrointestinal Carcinoid Tumor

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Urothelial Carcinoma

France, United States, Korea, Republic of, Belgium, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus, Poland
BeiGene

Completed

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

China
M.D. Anderson Cancer Center

Active, not recruiting

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...

United States
Harbin Medical University

Not yet recruiting

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

Extensive-stage Small-cell Lung Cancer
Trans Tasman Radiation Oncology Group
AstraZeneca

Recruiting

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy (CHEST RT)

Extensive-Stage Small-Cell Lung Cancer

Australia
National Cancer Institute (NCI)
NRG Oncology

Terminated

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditions

United States, Canada, China, Singapore
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Tang-Du Hospital

Recruiting

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Non-small Cell Lung Cancer

China
Stanford University

Completed

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United States
Emory University
National Cancer Institute (NCI); Pfizer; National Institutes of Health (NIH)

Completed

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Sarcoma | Head and Neck Cancer | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Stage IV Non-Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer and other conditions

United States
Eli Lilly and Company

Terminated

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Lung Cancer

Germany, Poland, Italy, Belgium, Romania
Akeso

Completed

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Fudan University

Unknown

Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Peking Union Medical College

Recruiting

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Non-small Cell Lung Cancer | EGFR T790M | Osimertinib | ddPCR

China
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
Columbia University

Terminated

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)

Non-Small Cell Lung Cancer

United States

Search clinical trials for: Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations